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Abstract 
Pegylated liposomal doxorubicin, or PLD, is a widely used agent in 
treating recurrent and refractory ovarian cancer. The brand name drug, Doxil® 
was the first FDA-approved PLD product used in the United States. In 2012, 
Doxil® supply issues prompted the FDA to approve the emergency importation of 
Lipodox™, which then was not FDA-approved, as an alternative to Doxil®, 
despite little data existing comparing the equivalency of the two. UNC Medical 
Center (UNCMC) has treated patients using both products based on availability. 
Due to the nuanced nature of liposomal drug products and the limited data 
concerning the therapeutic equivalency of these two drugs, outcomes of ovarian 
cancer patients treated with Lipodox™ were compared to those treated with 
Doxil®. This retrospective comparison suggests that the Doxil® drug shortage did 
not result in differences in patient outcomes when Lipodox™ was used as a 
monotherapy for relapsed and refractory ovarian cancer.  
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Introduction 
 Ovarian cancer is the leading cause of death among gynecological 
tumors.1 The American Cancer Society estimates that 22,280 women will be 
newly diagnosed with ovarian cancer in 2016 and that 14,240 will die from 
ovarian cancer.2 The exact cause of ovarian cancer is poorly understood, but is 
generally thought to be multi-faceted with endocrine, environmental, and genetic 
factors all contributing to the disease. Eighty-five to ninety percent of cases are 
non-hereditary and only 10-15% are considered familial or hereditary.3 Key 
genes for ovarian cancer include BRCA1, BRCA2, and p53 tumor suppressor 
gene.3 No effective ovarian cancer screening methods exist. Transvaginal 
ultrasound, pelvic exams, and CA-125 have all been investigated as potential 
screening tools but none have been sensitive or specific enough to warrant 
implementation.4  
 First-line treatment for ovarian cancer consists of platinum-based therapy, 
typically cisplatin or carboplatin with the addition of a taxane, either paclitaxel or 
docetaxel. Unfortunately, 60-80% of patients ultimately relapse.5 Second line 
treatment depends on a variety of factors, including patient or family 
convenience, prior toxicities experienced, insurance coverage, and quality of life. 
Additionally, second line treatment is dependent on a patient’s platinum-free 
interval (PFI), defined as the time between the end of the last treatment course 
and the re-occurrence of relapse or progression of the cancer. For platinum 
sensitive disease (PFI ≥6 months), second line treatment is a platinum-based 
therapy with the option of adding gemcitabine, bevacizumab, or pegylated 
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liposomal doxorubicin. For platinum resistant disease (PFI <6 months), second 
line options commonly used are topotecan, PLD, paclitaxel, and gemcitabine.4   
 Pegylated liposomal doxorubicin (PLD) is a widely used agent in the 
treatment of platinum-sensitive and platinum-resistant recurrent and refractory 
ovarian cancer.1 PLD consists of doxorubicin hydrochloride encased in a 100nm 
unilamellar liposome with PEG-linked phosphoethanolamine lipid. Compared to 
conventional doxorubicin, the liposomal formulation significantly increases 
circulation time from <1 hour for free doxorubicin to approximately 55 hours and 
has increased cytotoxic effects due to the enhanced permeability and retention 
(EPR) characteristics of tumor tissues.6 Additionally, the liposomal formulation 
reduces the significant cardiac toxicity often associated with free doxorubicin.7  
 
Doxil Drug Shortage and Study Background 
 Approved in 1995, Doxil® was the first PLD marketed in the United States. 
Starting in late 2011, Janssen Pharmaceuticals experienced various 
manufacturing and regulatory hurdles leading to a shortage in Doxil®, as well as 
other drugs produced in their Bedford Ohio plant (see appendix A).8 In response 
to recurrent shortages of Doxil®, the FDA temporarily approved the importation of 
Lipodox™, another PLD product manufactured by Sun Pharma, as an alternative 
to Doxil®.  
Although the products have very similar composition and characteristics 
(Table 1) there is little clinical data comparing their equivalence with regard to 
efficacy and toxicity.9 Two United States studies done in 2014 suggested that 
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Doxil® and Lipodox™ may have different clinical activity, resulting in different 
patient outcomes.10,11 The University of North Carolina Medical Center (UNCMC) 
has treated patients using both Doxil® and Lipodox™ based on product 
availability. Due to the nuanced nature of liposomal drug products and the limited 
data concerning the therapeutic equivalency of these two drugs, outcomes of 
ovarian cancer patients treated with Lipodox™ were compared to those treated 
with Doxil®. The two objectives of the study were: 
 To compare the clinical outcomes in patients treated with two different 
formulations of pegylated liposomal doxorubicin for recurrent or refractory 
ovarian cancer. 
 To assess the impact of the Doxil® supply shortage on patient outcomes. 
 
Methods 
 This study was a retrospective, single-center, chart review approved by 
the University of North Carolina – Chapel Hill Institutional Review Board (IRB 
#14-1913). Consent procedures were deemed unnecessary as this was a 
retrospective review with no patient contact. Patients were identified using 
electronic pharmacy dispensing records if they received either Lipodox™ or 
Doxil® at UNCMC. The chart abstraction dates were January 1, 2007 to July 30, 
2014. This date range was chosen in order to obtain comparable numbers of 
patients in the Doxil® group as the Lipodox™ group based on the time pre- and 
post-shortage of Doxil®. Patient charts were de-identified and reviewed to gather 
pertinent information using a data collection form (Appendix B). Platinum-free 
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interval (PFI) was defined as the interval from the last date of platinum-based 
therapy until documentation of progressive disease.  
 Inclusion criteria included female patients >18 years old treated at 
UNCMC with a PLD product between January 1, 2007 and July 30, 2014, and a 
diagnosis of recurrent or refractory ovarian cancer. Exclusion criteria included 
receiving PLD for disease other than ovarian cancer and receiving combination 
treatments (e.g. carboplatin in addition to PLD). After applying these inclusion 
and exclusion criteria, there were 16 patients in the Doxil® group, 20 patients in 
the Lipodox™ group, and 4 patients who received both PLD drugs who were 
analyzed as a separate group.  
 Outcome measures for this study included objective response rate (ORR) 
and time to progression. Objective response rates were based on the Response 
Evaluation Criteria in Solid Tumors (RECIST).12 Time to progression (TTP) was 
defined as objective tumor progression evidenced by either imaging results or 
symptomatic worsening based on the physician’s clinical judgement.  
 Statistical analyses were performed by the UNC Lineberger Biostatistics 
Shared Resource (BIOS Core). Wilcoxon p-values were used to analyze patient 
age, BMI, number of comorbidities, number of prior chemotherapy regimens, and 
PFI. Fisher p-values were used to analyze patient race, specific comorbidities, 
whether the patient had previously received PLD, and ORR. Kaplan-Meier 
analysis with log-rank testing was used for time to progression, with multivariable 
Cox regression used to control for differences in patient populations. All analyses 
were performed using SAS Statistical Software, version 9.3 (Cary, NC). 
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Results 
 The two patient populations had similar demographics with regard to age, 
race, body mass index (BMI), and the number of prior chemotherapy regimens 
(Table 2). Doxil® patients had more comorbidities than Lipodox™ patients 
(p=0.05). Doxil® patients also had a longer PFI (p=0.02), suggesting that their 
disease was initially more sensitive to platinum-based chemotherapy regimens.  
When comparing objective response rate using RECIST criteria (Table 3), 
no significant differences were observed between Doxil® and Lipodox™ (all 
groups comparison Fisher p-value=0.19). Additionally, when comparing overall 
response rate (CR+PR), the difference between Doxil® and Lipodox™ was not 
significant (6% vs. 25%, p=0.36).  
The Lipodox™ group had a median TTP of 213 days (95% CI, 98-404) 
and the Doxil® group had a median TTP of 123 days (95% CI, 95-164). A log-
rank test did not show significance with p=0.32 (Figure 1). After controlling for 
comorbidities and for PFI, there is no significant difference in TTP based on drug 
(hazard ratio 0.70, p=0.31; hazard ratio 0.86, p=0.68, respectively). 
 
Discussion and Conclusion 
 
Temporary importation of unapproved drugs is a strategy that the FDA 
turns to during domestic drug shortages. Often these unapproved drugs have 
only been studied in patient populations different from those in the United States. 
For instance, Lipodox™ clinical data is much more robust in Japanese and 
Taiwanese patients.13,14 For drugs which have been shown to be effective and 
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safe in foreign populations, clinicians and regulatory agencies must consider 
whether the same efficacy and safety can be extrapolated to patients living in the 
United States who may have different environmental exposures and cancer 
biology.  
  The results of this research suggest that there were no differences in 
therapeutic outcomes in recurrent or refractory ovarian cancer patients who 
received Lipodox™ compared to those who received Doxil®. Although Lipodox™ 
patients had a higher overall response rate and a longer TTP, the difference was 
not statistically significant even after controlling for differences in the patient 
population. After controlling for the greater number of comorbidities in the Doxil® 
group, the Lipodox™ hazard ratio was 0.70 (p=0.31). After controlling for the 
difference in PFI between the two groups, the Lipodox™ hazard ratio was 0.86 
(p=0.68). The data demonstrate no significant difference in overall response rate 
or TTP in patients who received Lipodox™ compared with those who received 
Doxil®. Therefore, this study suggests that the Doxil® drug shortage did not 
adversely affect treatment outcomes when Lipodox™ was used as a 
monotherapy for recurrent and refractory ovarian cancer.  
  Our findings in this study are different than those found by Berger JL et al. 
in a 2014 comparison of outcomes in 18 patients with recurrent epithelial ovarian 
cancer who received Lipodox™ compared with historical Doxil® controls.11 This 
study found that in their small population of patients who received a median of 
three prior chemotherapy regimens, Lipodox™ did not produce any complete or 
partial response as measured by RECIST. One reason for this conflict is the 
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patient population in this study was more heavily pre-treated than those in our 
study with a median of three prior chemotherapy regimens compared to a 
median of two regimens. This indicates ovarian cancer that may be more 
resistant to pharmacologic treatment. Additionally, their study only included 18 
patients in its analysis.  
 There were several limitations to our study which provide avenues for 
future research. First, due to several factors, only a small patient population was 
available for analysis in this retrospective chart review. Despite the date range 
spanning 7 years, only 40 patients met the inclusion criteria. The study only 
investigated PLD as a monotherapy but PLD is often used in combination with 
other agents in the relapsed and refractory setting. This is most relevant with 
platinum-sensitive relapsed disease where PLD is often used in conjunction with 
carboplatin. In platinum-resistant disease, bevacizumab is commonly used in 
combination with PLD. One potential area of future research is examining 
outcomes when different PLD formulations are used in combination with other 
agents. Another reason for the small patient population was due to the recurrent 
drug supply shortage. PLD was difficult to obtain over an extended time period 
and it is likely that physicians opted for alternate therapies for patients with 
relapsed disease.  
Lastly, this was a single center study. It is possible that the results of this 
study could be used as a basis for a larger comparison of outcomes of patients 
who received Doxil® vs. Lipodox™ with an analysis powered to detect a potential 
difference between Doxil® and Lipodox™.  Other hospitals in the UNC Health 
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Care system are now using the same electronic medical record so future 
research could include these hospitals’ patients, increasing the sample size and 
the power of the analysis to detect a true difference that may exist.  
Another direction for future research is further examination of patients who 
received both Doxil® and Lipodox™. A 2014 study in the United States showed 
ovarian cancer patients who received both Doxil® and Lipodox™ had a longer 
TTP and higher overall response rate compared to patients who received only 
one formulation of PLD.10 The patient population who received both drugs in our 
study was too small to analyze (n=4). If more patients are analyzed in future 
research, it would be interesting to see if there is benefit in receiving both Doxil® 
and Lipodox™. One potential mechanism of this therapeutic benefit is small 
differences in liposomal formulation resulting in alterations in how doxorubicin is 
unloaded from liposomes within tumor cells. This could lead to increased drug 
exposure at the tumor site when both Doxil® and Lipodox™ are administered. 
 
Conclusion 
This retrospective chart review is the largest study to date that directly 
compares outcomes of Lipodox™ vs. Doxil® therapy in recurrent and refractory 
ovarian cancer. The results of this study suggest that the PLD drug shortage did 
not result in differences in therapeutic outcomes in patients who received 
Lipodox™ compared to those who received Doxil® as a monotherapy for 
recurrent and refractory ovarian cancer. This data supports the use of either 
product in the event of a future PLD shortage.  
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Appendix A: Doxil® Shortage Timeline 
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Table 1: Comparison of Doxil and Lipodox9 
Characteristic Doxil® Lipodox™ 
Source Janssen Pharmaceuticals, 
United States 
Sun Pharma, India 
Active 
drug/concentration 
Doxorubicin HCl 2mg/mL 
encapsulated in Stealth® 
pegylated liposomal carrier 
Doxorubicin HCl 2mg/mL 




N- (carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-
snglycero-3 phosphoethanolamine sodium salt (MPEG-DSPE), 
fully hydrogenated soy phosphatidylcholine (HSPC), cholesterol.  
Greater than 90% of the drug is encapsulated in liposomes 
Inactive 
ingredients 
Ammonium sulfate, histidine, and sucrose; hydrochloric acid and / 




Labeled: 50 mg/m2 IV once every 4 weeks. 
Continue at least 4 months before assessing response to therapy 
Appearance Translucent, red dispersion 
Recommended 
Storage 
Refrigerate unopened vials. Avoid prolonged freezing (>1 month) 
Concentration 20 mg/10 ML SDV 
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Table 2: Patient Demographics 
Demographics Doxil® (n=16) Lipodox™ (n=20) 
Received both 
(n=4) 
Age, median (range), 
years 

















Body Mass Index, 
median (range), kg/m2 
24.1 (20.3 – 43.5) 24.9 (18 – 39) 28.0 (28.0 – 39) 
Comorbidities, median 3 2 1 
Prior chemotherapy 
regimens, median 
2 2 2 
Platinum-free interval 
(PFI), median (range), 
months 
7 (2 – 18) 3 (0 – 12) 2.5 (0 – 16) 
 
 
Table 3: Objective response rate using RECIST 





6% 5% 0% 
Partial response 0% 20% 25% 
Stable disease 13% 20% 50% 
Progressive 
disease 




25% 5% 0% 
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 Figure 1: Kaplan-Meier plot for Time to Progression (TTP) 
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Appendix B: Data Collection Form  
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